Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease
Introduction
Whereas delayed gastric emptying is believed to be a causative factor for producing delayed-on and motor fluctuation in Parkinson's disease (PD) [1], few studies have directly measured levodopa pharmacodynamics and gastric emptying together [2], [3]. In order to determine the relationship, we measured these two parameters in a single PD patients cohort.
Section snippets
Methods
Thirty-one patients who were diagnosed with PD [4] were enrolled in the study. They were 11 men and 20 women; age, 68.1 ± 7.8 years (mean ± standard deviation); disease duration, 4.2 ± 3.8 years; Modified Hoehn and Yahr stage 2.5 ± 0.71; Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Motor Score 18.37 ± 8.60; bowel movement < 3 times a week (constipation) in 20; all taking 301 mg ± 94 mg/day levodopa [as Menesit tablet [levodopa 100 mg/carbidopa 10 mg] in Japan]. Pharmacokinetic study was performed in
Results
Pharmacokinetic study showed that the plasma levodopa peak was at 2 hours in 42% (13/31 patients) whereas at 1 hour in 58% (18/31 patients), total of 50.7 ± 16.4 min (mean ± standard deviation) in all 31 patients (Fig. 1). The gastric emptying study showed that Tmax (13C) > 60 min was more common in patients with a plasma levodopa peak at 2 hours (14/18, 69%) than in those with a plasma levodopa peak at 1 hour (4/13, 22%) (p < 0.05) (Fig. 1).
The gastric emptying study also showed that 3 patients showed
Discussion
Previously, Evans et al. [2] measured gastric emptying time by 99mTc-diethyleletriamine-penta-acetic acid gastric scintigraphy and plasma levodopa concentration in 6 PD patients. However, he found no close relationship between these two parameters in his cohort. Dizdar et al. [3] administered the 13C-octanoic acid breath test and plasma levodopa concentration in one PD patient; he found delayed levodopa peak and slow gastric emptying time in this case. In the present study, we found a
Conflict of interest statement
None of the authors have conflict of interest.
Acknowledgments
Author contributions:
Hirokazu Doi has a role in acquisition, analysis and interpretation of data.
Ryuji Sakakibara has a role in study concept and design, acquisition of subjects and/or data, analysis and interpretation of data, and preparation of manuscript.
Mitsutoshi Sato has a role in acquisition of subjects and/or data.
Tohru Masaka has a role in acquisition of subjects and/or data.
Masahiko Kishi has a role in acquisition of subjects and/or data.
Akihiko Tateno has a role in acquisition of
References (12)
- et al.
Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test
Gastroenterology
(1993) - et al.
Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia
Gastroenterology
(2004) Multi-organ autonomic dysfunction in Parkinson disease
Parkinsonism Relat Disord
(2011)- et al.
Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: the QL-GAT study
Parkinsonism Relat Disord
(2011) - et al.
Management of motor complications in advanced Parkinson's disease
Mov Disord
(2007) - et al.
Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient
Neurology
(1981)
Cited by (86)
Classification of L-DOPA pharmacokinetics shapes and creating a predictive model
2023, Parkinsonism and Related DisordersImpact of outpatient gastroenterology consult on pharmacotherapy and management of gastrointestinal symptoms in Parkinson's Disease
2023, Clinical Parkinsonism and Related DisordersThe Physiology and Pharmacology of Diabetic Gastropathy Management
2022, Comprehensive PharmacologyParkinson's disease: the nutrition perspective
2022, Proceedings of the Nutrition SocietyManagement of Gastrointestinal Symptoms in Parkinson's Disease: A Comprehensive Review of Clinical Presentation, Workup, and Treatment
2024, Journal of Clinical GastroenterologyGastric-filling ultrasonography to evaluate gastric motility in patients with Parkinson's disease
2024, Frontiers in Neurology